Drug shortages are a persistent and serious problem in the United States, affecting patient care and health care costs. This article canvasses factors that contribute to drug shortages, such as manufacturing complexity, price, and quality inspection records. This article further proposes an early warning system and payment, contracting, and pricing innovations to mitigate drug shortages and offers data-driven recommendations to stakeholders looking to protect the supply of quality medicines.

Supply Chain Disruption
Drug shortages impede health care delivery in the United States, affecting patient care and increasing health care costs. While the immediate supply chain disruptions triggered by the COVID-19 pandemic are gradually resolving, the United States continues to face persistent drug shortages. In the first quarter of 2023, US active drug shortages were at their highest levels since 2014.

Drug shortages trigger ethical considerations regarding equity of access, information transparency, and crisis management. How should clinicians decide which patients should have access to scarce drugs and treatment alternatives? How should drug shortage information be communicated to patients and the public in a manner that is transparent, accurate, and responsible? What are the criteria for evaluating patient demand under crisis conditions?

This article quantitatively evaluates the impact of manufacturing complexity, price, and quality inspection records on drug shortages in the United States using publicly available data from government websites and the subscription-based Medicine Supply Map. By quantifying the factors correlated with drug shortages, stakeholders can make data-driven decisions to protect the supply of quality medicines, ultimately minimizing the ethical dilemmas triggered by drug shortages. Based on our findings, we advocate for the implementation of 2 strategic solutions aimed at fortifying the resilience of pharmaceutical supply chains: (1) investment in an early warning system for drug shortages and (2) exploration of payment, contracting, and pricing innovations.
Defining Drug Shortages in US Markets

Hospital pharmacists receive information about drug supply through wholesalers, manufacturers, and other hospitals, as well as the American Society of Health-System Pharmacists (ASHP) and the US Food and Drug Administration (FDA) shortage websites. While both ASHP and FDA report information on drug shortages for US markets, the organizations differ in their definitions and regulatory implications.

The FDA’s drug shortage list, managed by FDA drug shortage staff in the Center for Drug Evaluation and Research, focuses on national-level shortages of medically necessary drugs and requires an economic evaluation of manufacturers’ ability to supply the market for a given drug product to determine if the drug product is in shortage. According to the FDA website, “We consider a drug to be in shortage when the total supply of all versions of a commercially available product cannot meet the current demand, and a registered alternative manufacturer will not meet the current and/or projected demands for the potentially medically necessary use(s) at the patient level.”

ASHP defines a drug shortage more broadly as “a supply issue that affects how the pharmacy prepares or dispenses a drug product or influences patient care when prescribers must use an alternative agent.” Because ASHP does not require an economic determination of a national supply-demand imbalance for a drug to be included on the shortage list, as shown in Figure 1, there are more drug products on the ASHP shortage list than the FDA shortage list.

Figure 1. Comparison of 271 Drug Products on FDA and ASHP Drug Shortage Lists

Data obtained from the US Food and Drug Administration and the American Society of Health-System Pharmacists on June 26, 2023.

Abbreviations: FDA, Food and Drug Administration; ASHP, American Society of Health-System Pharmacists.

The FDA’s drug shortage reporting, unlike ASHP’s, triggers certain regulatory actions. When a drug is placed on the FDA’s drug shortage list, pursuant to the Drug Quality and Security Act of 2013, certain regulatory restrictions are removed for 503B outsourcing facilities. Such facilities may produce compounded drugs that “are essentially copies..."
of approved drugs.” Compounded drugs are made by pharmacists according to physicians’ prescriptions but are not FDA-approved and “pose a higher risk to patients ... because they do not undergo the FDA’s premarket review for safety, effectiveness, or quality.” This increased risk to patients is balanced against availability during a drug shortage event. In addition to removing regulatory restrictions for 503B compounding, the FDA can expedite review of manufacturing proposals (eg, changes in manufacturing sites or active pharmaceutical ingredient [API] sourcing), extend the expiry date for certain drug products, and exercise temporary import exceptions to mitigate the impact of drug shortages (eg, the FDA’s temporary import approval for cisplatin from China with non-US labeling).

**Shortages’ Influence on Health Outcomes**

**Cost of labor.** Hospital systems establish interdisciplinary teams to mitigate the impact of drug shortages. These drug shortage response teams are responsible for determining the organization’s supply forecast, evaluating alternative treatments, and changing patient care processes. Drug shortage response teams must also address ethical considerations related to patient access and patient disclosure, particularly in situations with few or no therapeutic alternatives. The administrative labor cost of managing US drug shortages was estimated to be $216 million per year in 2011 and $360 million per year in 2019.

**Cost of therapeutic alternatives.** Changing therapeutic solutions to combat drug shortages creates numerous cost, safety, and efficacy concerns. A 2014 study estimated that drug shortages increased health care costs by roughly $209 million in 2013 due to patients switching to more expensive therapeutic alternatives. Changes to patient care processes, unusual dosing regimens, and worse adverse-effect profiles also increase the risk of medication errors for patients.

**Cost to patients and society.** The true magnitude of drug shortages can only be measured through patient and societal impact. For example, the societal cost attributed to elevated mortality rates during the 2011 norepinephrine (a vasopressor used in treating septic shock) shortage has been estimated to be $13.7 billion. Because oncology drugs are inherently difficult to substitute due to their strict dosing regimens, often a shortage of a single drug product will drive supply risk for therapeutic alternative drug products, as in the case of cisplatin and carboplatin. As of June 26, 2023, 14 oncology drugs were in shortage, according to the FDA.6

Although a dollar amount cannot be placed on it, the risk of antimicrobial resistance (AMR) due to challenges to antibiotic supply, as exemplified by the recent amoxicillin shortage, also poses costs to patients and society. Effective antibiotic stewardship requires prescribers to issue “the right drug at the right dose at the right time for the right duration.” Switching to a more aggressive antibiotic tier based on supply constraints rather than patient need decreases the long-term efficacy of antibiotic drug products and poses a significant global health concern. Additionally, the prevalence of antibiotic drug shortages is intrinsically linked to an increased risk of use of substandard and falsified medicines. Poor-quality antibiotics increase the risk of AMR primarily through the administration of subtherapeutic dosing. Safeguarding the availability of quality antibiotics is thus critical to fighting AMR for patients globally.
Which Analytics Help Identify Drug Shortage Patterns?

Drug shortages stem from a complex interplay of economic, manufacturing, quality, and geographic factors. United States Pharmacopeia (USP) developed the Medicine Supply Map to identify, characterize, and quantify risks of disruption in the upstream pharmaceutical supply chain. USP identified 3 specific impacts of drug shortages, as defined by drugs’ inclusion on either the ASHP’s or FDA’s drug shortage list, at the drug product level.

**Impact of dosage form on drug shortages.** Injectable drug products are more complicated to manufacture than oral dosage forms. Compatibility studies, sterility assurance, and special handling considerations increase injectables’ manufacturing costs and risks of a negative quality event. These factors also increase the risk of a drug shortage. Figure 2 shows that, out of the 559 injectables tracked by the Medicine Supply Map, 178 (31.8%) were in shortage as of June 26, 2023. Rates of shortages are significantly lower for other dosage forms (see Figure 2).

**Figure 2.** Relative Shortage of 2476 Drug Products by Dosage Form

Data obtained from Medicine Supply Map on June 26, 2023.

**Impact of drug product unit prices on injectable drug shortages.** Lower-priced drugs experience more drug shortages, as manufacturers are less incentivized to invest in supply chain resilience. Figure 3 shows the relation between prices and drug product availability.
Impact of Unit Price on Supply Chain Vulnerability for Injectable Drug Products

Figure 3. Impact of Unit Price on Supply Chain Vulnerability for Injectable Drug Products

This analysis is based on publicly available pricing data from the US Department of Veterans Affairs\textsuperscript{25} and Medicare (Part B and Part D)\textsuperscript{26,27} on June 26, 2023.

Impact of manufacturing quality issues on drug shortages. Quality issues are correlated with drug shortages. According to the 2019 FDA report on drug shortages, “of 163 drugs that went into shortage between 2013 and 2017, 62 percent went into shortage after supply disruptions occurred that were associated with manufacturing or product quality problems.”\textsuperscript{28}

Drug manufacturers are required to test products to ensure that medicines meet the quality specifications approved by the FDA or articulated in a USP quality monograph. The FDA undertook 2442 risk-based drug product and biologics inspections in 2022.\textsuperscript{29} FDA inspections serve an important function by helping to protect patients and foster manufacturing quality compliance. Medicines that do not meet quality requirements must be reported to the FDA and withheld from the market.

To quantify the impact of quality issues on drug shortages, the Medicine Supply Map examined the relation between FDA inspection outcomes and drug shortages. We analyzed the proportion of inspections resulting in an official action indicated (OAI) record. The OAI inspection outcome means regulatory or administrative actions are recommended to correct quality issues identified in a manufacturing facility.\textsuperscript{30} Figure 4 shows that drug products produced at facilities with a higher portion of OAI inspection records were more likely to be in shortage.
Next Steps for Better Analytics and Sharper Surveillance

The journey of a molecule from an API to its final patient destination involves a network of specialized entities. API manufacturers create the primary therapeutic substance, drug product manufacturers transform the API into a consumable medication, distributors and wholesalers transport the drug products, and pharmacies help health care professionals administer medicines to patients. Because pharmaceutical supply chain data are heavily siloed within each specialized entity, solutions to drug shortages must bridge the information gaps across the supply chain. We propose the following solutions to strengthen patient access to quality medicines.

1. **Invest in an early warning system for drug shortages.** Enhancing insight into drug shortages and quantifying the relation between drugs in shortage and explanatory variables can enable stakeholders to make more informed decisions about how to protect patient access to quality medicines. Early warning systems should extend beyond drug product and API manufacturing to key starting materials and excipients to provide a more comprehensive view of risks of disruption in the pharmaceutical supply chain landscape.

2. **Explore payment, contracting, and pricing innovations.** Lower prices disincentivize manufacturers from investing in advanced quality systems and supply chain redundancy. A fundamental shift is needed in the market for lower-priced drugs to guarantee more certainty and predictability of both demand and supply and to increase the value placed on a drug’s supply chain resiliency and quality in addition to its price. Policy makers and public and private drug purchasers should explore the establishment and utilization of payment, contracting, and purchasing models that value and incentivize drug product quality and supply chain resilience.
Conclusion
The recent wave of new drug shortages provides the industry with an opportunity to rethink and reshape pharmaceutical supply chains and health care systems. We believe investments in an early warning analytics tool could help industry stakeholders make more informed supply chain decisions. A proactive, strategic, and collaborative approach that incorporates policy, industry, and health care stakeholders could help ensure a stable drug supply and promote better health outcomes for patients.

References


**Matt Christian, MSc** is the director of supply chain insights at US Pharmacopeia. His work involves identifying, characterizing, and quantifying pharmaceutical supply chain risk. He received an MSc degree in financial mathematics from Johns Hopkins University and a BS degree in chemical engineering from the University of Virginia.

**Wejdan Bagais, MSc** is a senior machine learning engineer at US Pharmacopeia. Her work involves data engineering and developing predictive models to tackle complex business problems. She received an MSc degree in health informatics from George Mason University and a BS degree in information technology from King Abdulaziz University.

**Citation**


**DOI**


**Conflict of Interest Disclosure**

Authors disclosed no conflicts of interest.

*The viewpoints expressed in this article are those of the author(s) and do not necessarily reflect the views and policies of the AMA.*